Osimertinib is a third-generation EGFR-TKI approved in many countries around the world for both EGFR-TKI sensitizing (exon 19 deletion & L858R point mutation in exon 21) and T790M resistance mutations in advanced stage NSCLC patients (7). This evidence concerns the gene EGFR and non-small cell lung carcinoma.